Document Detail


A comparison of dorzolamide/timolol-fixed combination versus bimatoprost in patients with open-angle glaucoma who are poorly controlled on latanoprost.
MedLine Citation:
PMID:  18627340     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The aim of this study was to evaluate the intraocular pressure (IOP) efficacy and safety of dorzolamide/timolol in fixed combination (DTFC) versus bimatoprost in open-angle glaucoma (OAG) patients poorly controlled (> or =21 mmHg) on latanoprost. METHODS: This was a prospective, double-masked, randomized, controlled, cross-over evaluation. After a 6-week wash-out period, the patients then returned for baseline diurnal curve testing every 2 h (8 AM to 8 PM). Patients with an IOP of 22-29 mmHg inclusive at 8 AMwere randomized to either bimatoprost dosed each evening or DTFC twice-daily. Patients returned in 8 weeks for the Period 1 diurnal curve and were switched to the opposite treatment. Patients again returned in 8 weeks for the Period 2 diurnal curve. RESULTS: Of the 29 patients, mean untreated baseline IOP (visit 2) was 24.6 +/- 2.6 mmHg and treatment mean IOP was statistically lower with bimatoprost 17.6 +/- 2.0 mmHg than for DTFC 18.8 +/- 2.5 mmHg (P = 0.03), as was the IOP range (P = 0.02) and IOP peak (P = 0.003). No significant differences were found between DTFC and bimatoprost at individual time points after a modified Bonferroni correction (>0.02). DTFC demonstrated a greater incidence of stinging or burning (n = 12) than bimatoprost (n = 0; P = < 0.0001). CONCLUSIONS: This study suggests that OAG patients generally can obtain similar IOP control at individual time points (when a Bonferroni correction is considered) by switching to either DTFC or bimatoprost, but overall diurnal control is statistically better with bimatoprost.
Authors:
Elizabeth D Sharpe; Robert D Williams; Jeanette A Stewart; Lindsay A Nelson; William C Stewart
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics     Volume:  24     ISSN:  1557-7732     ISO Abbreviation:  J Ocul Pharmacol Ther     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-07-30     Completed Date:  2009-01-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9511091     Medline TA:  J Ocul Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  408-13     Citation Subset:  IM    
Affiliation:
Glaucoma Consultants & Center for Eye Research, Mount Pleasant, SC, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Amides / administration & dosage*
Cloprostenol / administration & dosage,  analogs & derivatives*
Cross-Over Studies
Double-Blind Method
Drug Administration Schedule
Drug Combinations
Female
Glaucoma, Open-Angle / drug therapy*,  pathology
Humans
Male
Middle Aged
Prospective Studies
Prostaglandins F, Synthetic / administration & dosage*
Sulfonamides / administration & dosage*
Thiophenes / administration & dosage*
Timolol / administration & dosage*
Chemical
Reg. No./Substance:
0/Amides; 0/Drug Combinations; 0/Prostaglandins F, Synthetic; 0/Sulfonamides; 0/Thiophenes; 0/bimatoprost; 130209-82-4/latanoprost; 130693-82-2/dorzolamide; 26839-75-8/Timolol; 40665-92-7/Cloprostenol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intravitreal bevacizumab treatment for refractory diabetic macular edema.
Next Document:  Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7.